Resumen
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) that leads to severe neurological deficits. Due to their immunomodulatory and neuroprotective activities and their ability to promote the generation of oligodendrocytes, mesenchymal stem cells (MSCs) are currently being developed for autologous cell therapy in MS. As aging reduces the regenerative capacity of all tissues, it is of relevance to investigate whether MSCs retain their pro-oligodendrogenic activity with increasing age. We demonstrate that MSCs derived from aged rats have a reduced capacity to induce oligodendrocyte differentiation of adult CNS stem/progenitor cells. Aging also abolished the ability of MSCs to enhance the generation of myelin-like sheaths in demyelinated cerebellar slice cultures. Finally, in a rat model for CNS demyelination, aging suppressed the capability of systemically transplanted MSCs to boost oligodendrocyte progenitor cell (OPC) differentiation during remyelination. Thus, aging restricts the ability of MSCs to support the generation of oligodendrocytes and consequently inhibits their capacity to enhance the generation of myelin-like sheaths. These findings may impact on the design of therapies using autologous MSCs in older MS patients.
| Idioma original | Inglés |
|---|---|
| Páginas (desde-hasta) | 1510-1525 |
| Número de páginas | 16 |
| Publicación | GLIA |
| Volumen | 67 |
| N.º | 8 |
| DOI | |
| Estado | Publicada - ago 2019 |
Nota bibliográfica
Publisher Copyright:© 2019 The Authors. Glia published by Wiley Periodicals, Inc.
Huella
Profundice en los temas de investigación de 'Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination. / Rivera, Francisco J.; de la Fuente, Alerie G.; Zhao, Chao; Silva, Maria E.; Gonzalez, Ginez A.; Wodnar, Roman; Feichtner, Martina; Lange, Simona; Errea, Oihana; Priglinger, Eleni; O'Sullivan, Anna; Romanelli, Pasquale; Jadasz, Janusz J.; Brachtl, Gabriele; Greil, Richard; Tempfer, Herbert; Traweger, Andreas; Batiz, Luis Federico; Küry, Patrick; Couillard-Despres, Sebastien; Franklin, Robin J.M.; Aigner, Ludwig.
En: GLIA, Vol. 67, N.º 8, 08.2019, p. 1510-1525.Resultado de la investigación: Contribución a una revista › Artículo › revisión exhaustiva
TY - JOUR
T1 - Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination
AU - Rivera, Francisco J.
AU - de la Fuente, Alerie G.
AU - Zhao, Chao
AU - Silva, Maria E.
AU - Gonzalez, Ginez A.
AU - Wodnar, Roman
AU - Feichtner, Martina
AU - Lange, Simona
AU - Errea, Oihana
AU - Priglinger, Eleni
AU - O'Sullivan, Anna
AU - Romanelli, Pasquale
AU - Jadasz, Janusz J.
AU - Brachtl, Gabriele
AU - Greil, Richard
AU - Tempfer, Herbert
AU - Traweger, Andreas
AU - Batiz, Luis Federico
AU - Küry, Patrick
AU - Couillard-Despres, Sebastien
AU - Franklin, Robin J.M.
AU - Aigner, Ludwig
N1 - Funding Information: The authors would like to thank the following funding agencies for their support: Paracelsus Medical University PMU-FFF Long-Term Fellowship L-12/01/001-RIV and Stand-Alone Grant E-12/15/077-RIT [both to F.J.R.]; Chilean Comisión Nacional de Investigación Científica y Tecno-lógica [CONICYT] FONDECYT Program Regular Grant No. 1161787 [to F.J.R.], Regular Grant No. 1141015 [to L.F.B.]; Chilean CONICYT PCI Program Grant No. REDES170233 [to F.J.R.], Grant No. REDES180139 and Grant No. REDI170037; Chilean CONICYT FONDEF-IDeA Program Grant No. ID17AM0043 [to M.E.S. and F.J.R.]; European Union's Seventh Framework Programme [FP7/2007-2013] under grant agreements No. HEALTH-F2-2011-278850 [INMiND] and HEALTH-F2-2011-279288 [IDEA]). The work in the Küry laboratory was supported by the German Research Foundation (DFG; KU1934/2_1, KU1934/5-1) and the Christiane and Claudia Hempel Foundation for clinical and iBrain. The work in the Franklin laboratory was supported by grants from the UK Multiple Sclerosis Society and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, and a core support grant from the Wellcome Trust and MRC to the Wellcome-MRC Cambridge Stem Cell Institute. In addition, the present work was supported by the state of Salzburg (to L.A.). We thank Armin Schneider, Sygnis Pharma AG Heidelberg, Germany, for the MBP promoter construct. We disclose any conflict of interest. Funding Information: information Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Bavarian State Ministry of Sciences, Research and the Arts ForNeuroCell grant; Bundesministerium f?r Bildung und Forschung, Grant/Award Numbers: 01GG0706, 01GN0505, 0312134; Christiane and Claudia Hempel Foundation for Clinical and iBrain; Comisi?n Nacional de Investigaci?n Cient?fica y Tecnol?gica (CONICYT) ? Fondo Nacional de Desarrollo Cient?fico y Tecnol?gico (FONDECYT), Grant/Award Numbers: 1161787, 1141015; Comisi?n Nacional de Investigaci?n Cient?fica y Tecnol?gica (CONICYT) - Fondo de Fomento al Desarrollo Cient?fico y Tecnol?gico (FONDEF) - IDeA, Grant/Award Number: ID17AM0043; Comisi?n Nacional de Investigaci?n Cient?fica y Tecnol?gica (CONICYT) ? Programa de Cooperaci?n Internacional (PCI), Grant/Award Numbers: REDES170233, REDES180139, REDI170037; Deutsche Forschungsgemeinschaft, Grant/Award Numbers: KU1934/2_1, KU1934/5-1; European Union's Seventh Framework Programme (FP7/2007-2013; INMiND, IDEA), Grant/Award Numbers: HEALTH-F2-2011-278850, HEALTH-F2-2011-279288; Medical Research Council; PMU-FFF (Long-Term Fellowship, Stand-Alone Grant), Grant/Award Numbers: L-12/01/001-RIV, E-12/15/077-RIT; UK Multiple Sclerosis Society; Wellcome Trust; Wellcome-MRC Cambridge Stem Cell InstituteThe authors would like to thank the following funding agencies for their support: Paracelsus Medical University PMU-FFF Long-Term Fellowship L-12/01/001-RIV and Stand-Alone Grant E-12/15/077-RIT [both to F.J.R.]; Chilean Comisi?n Nacional de Investigaci?n Cient?fica y Tecnol?gica [CONICYT] FONDECYT Program Regular Grant No. 1161787 [to F.J.R.], Regular Grant No. 1141015 [to L.F.B.]; Chilean CONICYT PCI Program Grant No. REDES170233 [to F.J.R.], Grant No. REDES180139 and Grant No. REDI170037; Chilean CONICYT FONDEF-IDeA Program Grant No. ID17AM0043 [to M.E.S. and F.J.R.]; European Union's Seventh Framework Programme [FP7/2007-2013] under grant agreements No. HEALTH-F2-2011-278850 [INMiND] and HEALTH-F2-2011-279288 [IDEA]). The work in the K?ry laboratory was supported by the German Research Foundation (DFG; KU1934/2_1, KU1934/5-1) and the Christiane and Claudia Hempel Foundation for clinical and iBrain. The work in the Franklin laboratory was supported by grants from the UK Multiple Sclerosis Society and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, and a core support grant from the Wellcome Trust and MRC to the Wellcome-MRC Cambridge Stem Cell Institute. In addition, the present work was supported by the state of Salzburg (to L.A.). We thank Armin Schneider, Sygnis Pharma AG Heidelberg, Germany, for the MBP promoter construct. We disclose any conflict of interest. Funding Information: Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Bavarian State Ministry of Sciences, Research and the Arts ForNeuroCell grant; Bundesministerium für Bildung und Forschung, Grant/Award Numbers: 01GG0706, 01GN0505, 0312134; Christiane and Claudia Hempel Foundation for Clinical and iBrain; Comisión Nacional de Investigación Científica y Tecnológica (CONICYT) – Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT), Grant/ Award Numbers: 1161787, 1141015; Comisión Nacional de Investigación Científica y Tecnológica (CONICYT) - Fondo de Fomento al Desarrollo Científico y Tecnológico (FONDEF) - IDeA, Grant/Award Number: ID17AM0043; Comisión Nacional de Investigación Científica y Tecnológica (CONICYT) – Programa de Cooperación Internacional (PCI), Grant/Award Numbers: REDES170233, REDES180139, REDI170037; Deutsche Forschungsgemeinschaft, Grant/ Award Numbers: KU1934/2_1, KU1934/5-1; European Union's Seventh Framework Programme (FP7/2007-2013; INMiND, IDEA), Grant/Award Numbers: HEALTH-F2-2011-278850, HEALTH-F2-2011-279288; Medical Research Council; PMU-FFF (Long-Term Fellowship, Stand-Alone Grant), Grant/Award Numbers: L-12/01/001-RIV, E-12/15/077-RIT; UK Multiple Sclerosis Society; Wellcome Trust; Wellcome-MRC Cambridge Stem Cell Institute Publisher Copyright: © 2019 The Authors. Glia published by Wiley Periodicals, Inc.
PY - 2019/8
Y1 - 2019/8
N2 - Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) that leads to severe neurological deficits. Due to their immunomodulatory and neuroprotective activities and their ability to promote the generation of oligodendrocytes, mesenchymal stem cells (MSCs) are currently being developed for autologous cell therapy in MS. As aging reduces the regenerative capacity of all tissues, it is of relevance to investigate whether MSCs retain their pro-oligodendrogenic activity with increasing age. We demonstrate that MSCs derived from aged rats have a reduced capacity to induce oligodendrocyte differentiation of adult CNS stem/progenitor cells. Aging also abolished the ability of MSCs to enhance the generation of myelin-like sheaths in demyelinated cerebellar slice cultures. Finally, in a rat model for CNS demyelination, aging suppressed the capability of systemically transplanted MSCs to boost oligodendrocyte progenitor cell (OPC) differentiation during remyelination. Thus, aging restricts the ability of MSCs to support the generation of oligodendrocytes and consequently inhibits their capacity to enhance the generation of myelin-like sheaths. These findings may impact on the design of therapies using autologous MSCs in older MS patients.
AB - Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) that leads to severe neurological deficits. Due to their immunomodulatory and neuroprotective activities and their ability to promote the generation of oligodendrocytes, mesenchymal stem cells (MSCs) are currently being developed for autologous cell therapy in MS. As aging reduces the regenerative capacity of all tissues, it is of relevance to investigate whether MSCs retain their pro-oligodendrogenic activity with increasing age. We demonstrate that MSCs derived from aged rats have a reduced capacity to induce oligodendrocyte differentiation of adult CNS stem/progenitor cells. Aging also abolished the ability of MSCs to enhance the generation of myelin-like sheaths in demyelinated cerebellar slice cultures. Finally, in a rat model for CNS demyelination, aging suppressed the capability of systemically transplanted MSCs to boost oligodendrocyte progenitor cell (OPC) differentiation during remyelination. Thus, aging restricts the ability of MSCs to support the generation of oligodendrocytes and consequently inhibits their capacity to enhance the generation of myelin-like sheaths. These findings may impact on the design of therapies using autologous MSCs in older MS patients.
KW - CNS stem and progenitor cells
KW - aging
KW - cell therapy
KW - mesenchymal stem cells
KW - multiple sclerosis
KW - oligodendrocytes
KW - remyelination
UR - http://www.scopus.com/inward/record.url?scp=85065097226&partnerID=8YFLogxK
U2 - 10.1002/glia.23624
DO - 10.1002/glia.23624
M3 - Article
C2 - 31038798
AN - SCOPUS:85065097226
VL - 67
SP - 1510
EP - 1525
JO - GLIA
JF - GLIA
SN - 0894-1491
IS - 8
ER -